An Australian vote for pharma: generics
This article was originally published in Scrip
Leading brands that are set to lose patent protection in 2010-12 collectively generated $1.08 billion in sales in Australia in 2009. Products facing generic competition in Australia over this period include Wyeth (Pfizer's) Enbrel (etanercept), Pfizer's Lipitor (atorvastatin) and Lilly's Zyprexa (olanzapine). In 2012, $984 million worth of products will go off-patent, most prominently Lipitor.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.